Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1/NF-κB Signaling Pathway

Sepsis is a leading cause of death in patients with severe infection worldwide. Remifentanil is an ultra-short-acting, potent opioid analgesic. In the study, we aimed to investigate the role and underlying mechanism of remifentanil in lipopolysaccharide- (LPS-) induced inflammation in human aortic e...

Full description

Bibliographic Details
Main Authors: Jian-ning Zhang, Yang Ma, Xi-yan Wei, Ke-yin Liu, Hao Wang, Hui Han, Yi Cui, Ming-xiang Zhang, Wei-dong Qin
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2019/3013716

Similar Items